Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business capital investment

Apollo KKR Close Bayer LARC Capital Solution

Analysis based on 7 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026

Sentiment
15
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The closing of the 3 billion euro capital solution provides Bayer with balance-sheet relief and improved financial flexibility, which is modestly positive for Bayer credit and equity sentiment while signaling continued sponsor appetite for large German blue-chip capital solutions. For Apollo and KKR & Co., the deal reinforces their private capital deployment pipelines and fee-generating asset growth, a mildly supportive signal for alternative asset managers.

pharmaceuticals asset management private equity

Apollo Global Management announced on September 16, 2026 that Apollo-managed funds and affiliates closed a 3 billion euro capital solution for Bayer, a transaction first announced on July 10, 2026. KKR & Co. joined Apollo as a significant minority participant in the investment, a detail not disclosed in Bayer's original July announcement. Under the transaction, Apollo and KKR & Co. invested equity capital into a newly established entity holding Bayer's long-acting reversible contraceptives (LARC) business. Bayer retains a majority stake in the entity and continues to exercise full operational control over the business, with no changes to the LARC strategy. The LARC activities remain part of the Bayer Pharmaceuticals Division and the entity stays fully consolidated in Bayer's financial statements. Bayer CFO Judith Hartmann said in July that the transaction strengthens the company's capital structure while preserving operational control, and enhances financial flexibility amid increased liquidity requirements related to bond maturities and litigation. Apollo Partner Jamshid Ehsani said Apollo has committed to deploying more than 100 billion dollars in Germany over the coming decade. Bayer was advised by Bank of America and Deutsche Bank as financial advisors and by Linklaters as legal advisor. Centerview Partners advised the Apollo funds, with Latham & Watkins, Paul, Weiss, Rifkind, Wharton & Garrison, and NautaDutilh as legal counsel. The deal was subject to antitrust approval and closed within the expected third quarter of 2026 window.

85 Apollo Global Management closed capital solution Bayer
80 Bayer signed agreement Apollo Global Management
75 Bayer secured equity capital
70 KKR & Co. joined as minority participant Bayer
stock
Apollo originated and led the 3 billion euro capital solution for Bayer through its High Grade Capital Solutions platform, closing the deal on September 16, 2026. The transaction expands Apollo's fee-generating assets and supports its stated commitment to deploy over 100 billion dollars in Germany.
Importance 95.0 Sentiment 25.0
stock
Bayer secured and closed 3 billion euros in equity capital for its LARC business while retaining majority ownership and full operational control. The capital strengthens Bayer's balance sheet amid bond maturities and litigation costs.
Importance 95.0 Sentiment 20.0
stock
KKR & Co. joined Apollo as a significant minority participant in the Bayer LARC investment, a role not disclosed in Bayer's original July announcement. The participation adds to KKR's healthcare private equity exposure.
Importance 70.0 Sentiment 15.0
per
Apollo Partner Jamshid Ehsani publicly commented on the closing, framing the deal as a bespoke capital solution for a blue-chip German company and reiterating Apollo's long-term commitment to Germany.
Importance 40.0 Sentiment 10.0
per
Bayer CFO Judith Hartmann described the transaction in July as a strategic financing solution that strengthens Bayer's capital structure while preserving operational control over the LARC business.
Importance 30.0 Sentiment 10.0
cnt
Germany is the domicile of Bayer and the target of Apollo's stated 100 billion dollar deployment commitment, highlighting continued foreign private capital interest in German blue-chip companies.
Importance 25.0 Sentiment 10.0
curr
The transaction is denominated in euro, with the 3 billion euro capital solution representing a sizable euro-denominated private capital deployment.
Importance 20.0 Sentiment 5.0
stock
Bank of America served as a financial advisor to Bayer on the transaction, earning advisory fees.
Importance 15.0 Sentiment 5.0
stock
Deutsche Bank served as a financial advisor to Bayer on the transaction, earning advisory fees.
Importance 15.0 Sentiment 5.0
priv
Centerview Partners served as financial advisor to the Apollo funds on the transaction.
Importance 15.0 Sentiment 5.0
curr
Apollo's stated commitment to deploy more than 100 billion dollars in Germany over the coming decade is referenced in US dollars.
Importance 10.0 Sentiment 0.0
priv
Latham & Watkins acted as legal counsel to the Apollo funds on the transaction.
Importance 10.0 Sentiment 0.0
priv
Paul, Weiss, Rifkind, Wharton & Garrison acted as legal counsel to the Apollo funds on the transaction.
Importance 10.0 Sentiment 0.0
priv
NautaDutilh acted as legal counsel to the Apollo funds on the transaction.
Importance 10.0 Sentiment 0.0
priv
Linklaters acted as legal advisor to Bayer on the transaction.
Importance 10.0 Sentiment 0.0
+ 1 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.